Literature DB >> 229150

Thyrotropin receptor-adenylate cyclase system in plasma membranes from normal and diseased human thyroid glands.

P Carayon, M Guibout, S Lissitzky.   

Abstract

Thyrotropin binding characteristics and adenylate cyclase (AC) activity of thyroid plasma membranes were studied in 52 tissues from normal and diseased human thyroids. Data from normal glands, Graves' goiters, non toxic multinodular goiters and nodular and perinodular tissue of toxic nodular goiters show the same basal, TSH- and NaF- stimulated adenylate cyclase activities (no. = 45; 34.1 +/- 3.2 (m +/- SE), 378 +/- 43, 298 +/- 48 pmol cAMP x min-1 x mg membrane protein-1), the same stimulability of AC by TSH (11.3 +/- 1.4--fold over basal level) and by NaF (8.1 +/- 1.8-fold), the same apparent TSH binding equilibrium constants (5.6 +/- 0.7 and 406 +/- 57 nM) and the same TSH binding site concentrations (2.2 +/- 0.4, 27.8 +/- 5.9 pmol x mg membrane protein-1). Alterations of the TSH receptor and of the AC were detected in membranes from tumoral and metastatic lymph node tissues from thyroid papillary carcinoma and in the thyroid tissue from post-radioiodide therapy thyroiditis. These observations suggest that: (i) hyperthyroidism in Graves' disease or toxic nodular goiter does not result in and is not a consequence of an alteration in the TSH receptor-adenylate cyclase system; (ii) there is no evidence supporting a relationship between the studied membrane properties and clinical or histological status; (iii) membrane abnormalities detected in thyroid carcinoma vary widely; (iv) studies of these membrane alterations might be of interest in the therapeutic management of thyroid carcinoma and may lead to a better understanding of the receptor-adenylate system.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 229150     DOI: 10.1007/BF03350977

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

1.  Cooperativity in ligand binding: a new graphic analysis.

Authors:  P De Meyts; J Roth
Journal:  Biochem Biophys Res Commun       Date:  1975-10-27       Impact factor: 3.575

2.  Adenylate cyclase and protein phosphokinase activities in human thyroid. Comparison of normal glands, hyperfunctional nodules and carcinomas.

Authors:  G Sand; A Jortay; R Pochet; J E Dumont
Journal:  Eur J Cancer       Date:  1976-06       Impact factor: 9.162

3.  Thyrotropin-binding properties of isolated thyroid cells and their purified plasma membranes. Relation of thyrotropin-specific binding to adenylate-cyclase activation.

Authors:  B Verrier; G Fayet; S Lissitzky
Journal:  Eur J Biochem       Date:  1974-03-01

4.  Adenosine 3',5' cyclic monophosphate assay at 10-15 mole level.

Authors:  H L Cailla; M S Racine-Weisbuch; M A Delaage
Journal:  Anal Biochem       Date:  1973-12       Impact factor: 3.365

5.  Enzymatic radioiodination of porcine thyroid-stimulating hormone.

Authors:  P Jaquet; G Hennen; S Lissitzky
Journal:  Biochimie       Date:  1974       Impact factor: 4.079

6.  The binding of thyrotropin to isolated bovine thyroid plasma membranes.

Authors:  S M Amir; T F Carraway; L D Kohn; R J Winand
Journal:  J Biol Chem       Date:  1973-06-10       Impact factor: 5.157

7.  Abnormal adenylate cyclase activity and altered membrane gangliosides in thyroid cells from patients with Graves' disease.

Authors:  G Lee; E F Grollman; S M Aloj; L D Kohn; R J Winand
Journal:  Biochem Biophys Res Commun       Date:  1977-07-11       Impact factor: 3.575

8.  T.S.H. receptor and adenylate cyclase in undifferentiated thyroid carcinoma.

Authors:  Y Abe; Y Ichikawa; M Homma; K Ito; T Mimura
Journal:  Lancet       Date:  1977-09-03       Impact factor: 79.321

9.  The interaction of radioiodinated thyrotropin with human plasma membranes from normal and diseased thyroid glands. Relation of thyrotropin binding to adenylate cyclase activity.

Authors:  P Carayon; M Guibout; S Lissitzky
Journal:  Ann Endocrinol (Paris)       Date:  1979       Impact factor: 2.478

10.  1-Ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo-(3,4-b)-pyridine-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009)--a potent new inhibitor of cyclic 3',5'-nucleotide phosphodiesterases.

Authors:  M Chasin; D N Harris; M B Phillips; S M Hess
Journal:  Biochem Pharmacol       Date:  1972-09-15       Impact factor: 5.858

View more
  4 in total

1.  Morphological demonstration and quantification of TSH binding sites in neoplastic and non-neoplastic thyroid tissues. An autoradiographic study using 125I-labelled thyrotropin.

Authors:  S Schröder; H W Müller-Gärtner; R Schroiff; P Schmiegelow; A Niendorf; W Böcker
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

2.  Mechanisms for increased adenylate cyclase responsiveness to TSH in neoplastic human thyroid tissue.

Authors:  O H Clark; P L Gerend; R A Nissenson
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

3.  A fresh look at an old thyroid disease: euthyroid and hyperthyroid nodular goiter.

Authors:  H Studer
Journal:  J Endocrinol Invest       Date:  1982 Jan-Feb       Impact factor: 4.256

4.  Autoradiographical evidence for increased thyrotropin binding to autonomously functioning thyroid gland tissue.

Authors:  H W Müller-Gärtner; M Jessel; C Schneider; V Bay
Journal:  J Endocrinol Invest       Date:  1988-03       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.